The technology is versatile, capable of administering various compounds irrespective of the drug’s properties, from the leuprolide implant for prostate cancer to salmon calcitonin for osteoporosis and Paget’s disease, typically implanted subcutaneously in the upper arm. This evidence concerns the gene CALCA and prostate carcinoma.